{"rows":[{"id":5981,"title":"Psilocybin-Assisted Therapy in Depressive Disorders: Clinical Governance, Safety, and Translational Challenges","authors":"Szilvia Salima Bartha Msc In Business Administration","journal":null,"publication_date":"2026-10-05","publication_year":2026,"doi":"10.13140/rg.2.2.17829.05608","pubmed_id":null,"openalex_id":"https://openalex.org/W7220414206","source_url":"https://doi.org/10.13140/rg.2.2.17829.05608","substance_tags":"psilocybin","topic_tags":"Depression,Clinical Trial,Safety","study_type":"Clinical Trial","source_name":"OpenAlex","publication_status":"published","date_added":"2026-10-07 01:20:24","last_checked":"2026-10-08 01:20:23","bibtex":null,"source_record_id":"DOI:10.13140/rg.2.2.17829.05608","abstract_available":false,"abstract_source":null,"abstract_source_url":null,"abstract_redistributed":false,"text_rights_status":"not_applicable_no_text","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.13140/rg.2.2.17829.05608","source_url":"https://doi.org/10.13140/rg.2.2.17829.05608","doi":"10.13140/rg.2.2.17829.05608","pmid":"","publication_date":"2026-10-05","importer_version":"2.1.3","text_redistributed":false}},{"id":5980,"title":"Caution before canonisation: a clinical and implementation science perspective on psychedelics","authors":"Andreas Paris, Foteïni Thoma, Aikaterini Velentza, Panagiota Pavlopoulou, Giorgos Metaxas","journal":"Frontiers in Psychiatry","publication_date":"2026-10-05","publication_year":2026,"doi":"10.3389/fpsyt.2026.1922928","pubmed_id":null,"openalex_id":"https://openalex.org/W7220367324","source_url":"https://doi.org/10.3389/fpsyt.2026.1922928","substance_tags":"psilocybin","topic_tags":"Depression,PTSD,Addiction,Spirituality,Clinical Trial,Safety","study_type":"Clinical Trial","source_name":"OpenAlex","publication_status":"published","date_added":"2026-10-07 01:20:24","last_checked":"2026-10-08 01:20:23","bibtex":null,"source_record_id":"DOI:10.3389/fpsyt.2026.1922928","abstract_available":true,"abstract_source":"OpenAlex","abstract_source_url":"https://doi.org/10.3389/fpsyt.2026.1922928","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.3389/fpsyt.2026.1922928","source_url":"https://doi.org/10.3389/fpsyt.2026.1922928","doi":"10.3389/fpsyt.2026.1922928","pmid":"","publication_date":"2026-10-05","importer_version":"2.1.3","text_redistributed":false}},{"id":5979,"title":"Psilocybin use, mental health treatment utilization, and unmet treatment need among US individuals with depression.","authors":"Eun AC, Yang KH, Palamar JJ","journal":"Psychological medicine","publication_date":"2026-10-06","publication_year":2026,"doi":"10.1017/s0033291726106163","pubmed_id":"42834832","openalex_id":null,"source_url":"https://pubmed.ncbi.nlm.nih.gov/42834832/","substance_tags":"psilocybin","topic_tags":"Depression,Addiction,Observational Study","study_type":"Observational Study","source_name":"PubMed","publication_status":"published","date_added":"2026-10-07 01:20:05","last_checked":"2026-10-08 01:20:07","bibtex":null,"source_record_id":"PMID:42834832","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/42834832/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:42834832","source_url":"https://pubmed.ncbi.nlm.nih.gov/42834832/","doi":"10.1017/s0033291726106163","pmid":"42834832","publication_date":"2026-10-06","importer_version":"2.1.3","text_redistributed":false}},{"id":5977,"title":"Therapists’ Perspectives on the Psychotherapeutic Support in Psilocybin Treatment for Major Depressive Disorder: Insights from a Randomized Controlled Trial","authors":"Kjellgren A, Lundberg J, Yngwe H, Ekman CJ, Tiger M, Ljunglöf T, Stridh F, Beckman M.","journal":"Research Square","publication_date":"2026-10-05","publication_year":2026,"doi":"10.21203/rs.3.rs-10879308/v1","pubmed_id":null,"openalex_id":null,"source_url":"https://doi.org/10.21203/rs.3.rs-10879308/v1","substance_tags":"psilocybin","topic_tags":"Depression,Clinical Trial,Randomized Controlled Trial","study_type":"Randomized Controlled Trial","source_name":"Europe PMC","publication_status":"preprint","date_added":"2026-10-06 01:20:24","last_checked":"2026-10-08 01:20:20","bibtex":null,"source_record_id":"DOI:10.21203/rs.3.rs-10879308/v1","abstract_available":true,"abstract_source":"Europe PMC","abstract_source_url":"https://doi.org/10.21203/rs.3.rs-10879308/v1","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Europe PMC","source_record_id":"DOI:10.21203/rs.3.rs-10879308/v1","source_url":"https://doi.org/10.21203/rs.3.rs-10879308/v1","doi":"10.21203/rs.3.rs-10879308/v1","pmid":"","publication_date":"2026-10-05","importer_version":"2.1.3","text_redistributed":false}},{"id":5976,"title":"An Open-Label Multidose Psilocybin Intervention for Obsessive-Compulsive Disorder.","authors":"Tiwari, P.; Nayak, S. M.; Sepeda, N. D.; Ehrenkranz, R.; Levine, M. A.; Rohde, J. S.; Miller, E.; Beritela, C. M.; Scott, J. V.; Nestadt, G.; Barrett, F. S.; Yaden, D. B.","journal":"medRxiv","publication_date":"2026-10-05","publication_year":2026,"doi":"10.64898/2026.10.01.26364511","pubmed_id":null,"openalex_id":null,"source_url":"https://doi.org/10.64898/2026.10.01.26364511","substance_tags":"psilocybin","topic_tags":"Depression,Anxiety,OCD,Consciousness,Mystical Experience,Clinical Trial,Healthcare Workers,Safety","study_type":"Clinical Trial","source_name":"medRxiv","publication_status":"preprint","date_added":"2026-10-06 01:20:24","last_checked":"2026-10-08 01:20:45","bibtex":null,"source_record_id":"DOI:10.64898/2026.10.01.26364511","abstract_available":true,"abstract_source":"medRxiv","abstract_source_url":"https://doi.org/10.64898/2026.10.01.26364511","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"medRxiv","source_record_id":"DOI:10.64898/2026.10.01.26364511","source_url":"https://doi.org/10.64898/2026.10.01.26364511","doi":"10.64898/2026.10.01.26364511","pmid":"","publication_date":"2026-10-05","importer_version":"2.1.3","text_redistributed":false}},{"id":5975,"title":"Study Participant Perceptions of the Relevance of Therapist and Study Team Personal Psychedelic Experience","authors":"Benjamin R. Lewis, Eric L. Garland, Zach Schwartz, Yitong Xin, Kevin Byrne, Kious Brent","journal":"Psychedelics","publication_date":"2026-10-01","publication_year":2026,"doi":"10.1016/j.psyche.2026.100041","pubmed_id":null,"openalex_id":"https://openalex.org/W7218519509","source_url":"https://doi.org/10.1016/j.psyche.2026.100041","substance_tags":"psilocybin","topic_tags":"Depression,Anxiety,Spirituality,Randomized Controlled Trial,Healthcare Workers","study_type":"Randomized Controlled Trial","source_name":"OpenAlex","publication_status":"published","date_added":"2026-10-05 01:20:20","last_checked":"2026-10-08 01:20:23","bibtex":null,"source_record_id":"DOI:10.1016/j.psyche.2026.100041","abstract_available":true,"abstract_source":"OpenAlex","abstract_source_url":"https://doi.org/10.1016/j.psyche.2026.100041","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.1016/j.psyche.2026.100041","source_url":"https://doi.org/10.1016/j.psyche.2026.100041","doi":"10.1016/j.psyche.2026.100041","pmid":"","publication_date":"2026-10-01","importer_version":"2.1.3","text_redistributed":false}},{"id":5966,"title":"F25. COMPARING PSILOCYBIN-ASSISTED THERAPY AND SSRIS IN THE TREATMENT OF LATE-LIFE DEPRESSION","authors":"Lall Talia, Lin Anabel, Espinosa Juan","journal":"The American Journal of Geriatric Psychiatry","publication_date":"2026-10-01","publication_year":2026,"doi":"10.1016/j.jagp.2026.03.128","pubmed_id":null,"openalex_id":null,"source_url":"https://doi.org/10.1016/j.jagp.2026.03.128","substance_tags":"psilocybin","topic_tags":"Depression","study_type":"Other","source_name":"Crossref","publication_status":"published","date_added":"2026-10-01 01:20:24","last_checked":"2026-10-08 01:20:19","bibtex":null,"source_record_id":"DOI:10.1016/j.jagp.2026.03.128","abstract_available":false,"abstract_source":null,"abstract_source_url":null,"abstract_redistributed":false,"text_rights_status":"not_applicable_no_text","text_license_uri":null,"source_provenance":{"source_name":"Crossref","source_record_id":"DOI:10.1016/j.jagp.2026.03.128","source_url":"https://doi.org/10.1016/j.jagp.2026.03.128","doi":"10.1016/j.jagp.2026.03.128","pmid":"","publication_date":"2026-10-01","importer_version":"2.1.3","text_redistributed":false}},{"id":5964,"title":"MedCheck: Drugmakers Advance Psilocybin, Oral Pregnanolone for MDD, Plus FDA Approves Pediatric Tourette's Drug, and More","authors":"Richmond Linda M.","journal":"Psychiatric News","publication_date":"2026-10-01","publication_year":2026,"doi":"10.1176/appi.pn.2026.10.10.1","pubmed_id":null,"openalex_id":"https://openalex.org/W7214993352","source_url":"https://doi.org/10.1176/appi.pn.2026.10.10.1","substance_tags":"psilocybin","topic_tags":"Depression","study_type":"Other","source_name":"Crossref","publication_status":"published","date_added":"2026-10-01 01:20:23","last_checked":"2026-10-08 01:20:19","bibtex":null,"source_record_id":"DOI:10.1176/appi.pn.2026.10.10.1","abstract_available":false,"abstract_source":null,"abstract_source_url":null,"abstract_redistributed":false,"text_rights_status":"not_applicable_no_text","text_license_uri":null,"source_provenance":{"source_name":"Crossref","source_record_id":"DOI:10.1176/appi.pn.2026.10.10.1","source_url":"https://doi.org/10.1176/appi.pn.2026.10.10.1","doi":"10.1176/appi.pn.2026.10.10.1","pmid":"","publication_date":"2026-10-01","importer_version":"2.1.3","text_redistributed":false}},{"id":5963,"title":"Reduced egocentricity after psilocybin in patients with alcohol use disorder: a pilot randomized controlled trial","authors":"Bukowski, H.; de Timary, P.; Belahda, D.; Igounenc, N.; Mura, T.; Serrand, C.; Luquiens, A.","journal":"medRxiv","publication_date":"2026-09-29","publication_year":2026,"doi":"10.64898/2026.09.26.26364086","pubmed_id":null,"openalex_id":null,"source_url":"https://doi.org/10.64898/2026.09.26.26364086","substance_tags":"psilocybin","topic_tags":"Depression,Addiction,Mechanism of Action,Clinical Trial,Randomized Controlled Trial","study_type":"Randomized Controlled Trial","source_name":"medRxiv","publication_status":"preprint","date_added":"2026-09-30 01:20:46","last_checked":"2026-10-06 01:21:04","bibtex":null,"source_record_id":"DOI:10.64898/2026.09.26.26364086","abstract_available":true,"abstract_source":"medRxiv","abstract_source_url":"https://doi.org/10.64898/2026.09.26.26364086","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"medRxiv","source_record_id":"DOI:10.64898/2026.09.26.26364086","source_url":"https://doi.org/10.64898/2026.09.26.26364086","doi":"10.64898/2026.09.26.26364086","pmid":"","publication_date":"2026-09-29","importer_version":"2.1.3","text_redistributed":false}},{"id":5961,"title":"Worsening of Depression and Anxiety With Psilocybin: A Case Report in Cyclothymia.","authors":"Ghaemi SN.","journal":"The Journal of clinical psychiatry","publication_date":"2026-09-30","publication_year":2026,"doi":"10.4088/jcp.26cr16608","pubmed_id":"42814595","openalex_id":"https://openalex.org/W7214730919","source_url":"https://doi.org/10.4088/jcp.26cr16608","substance_tags":"psilocybin","topic_tags":"Depression,Anxiety,Case Report","study_type":"Case Report","source_name":"Europe PMC","publication_status":"published","date_added":"2026-09-30 01:20:19","last_checked":"2026-10-07 01:20:21","bibtex":null,"source_record_id":"PMID:42814595","abstract_available":false,"abstract_source":null,"abstract_source_url":null,"abstract_redistributed":false,"text_rights_status":"not_applicable_no_text","text_license_uri":null,"source_provenance":{"source_name":"Europe PMC","source_record_id":"PMID:42814595","source_url":"https://doi.org/10.4088/jcp.26cr16608","doi":"10.4088/jcp.26cr16608","pmid":"42814595","publication_date":"2026-09-30","importer_version":"2.1.3","text_redistributed":false}},{"id":5959,"title":"Psilocybin for Treatment-Resistant Major Depression: Efficacy, Safety and Therapeutic Mechanisms","authors":"Lea Julia Mertens","journal":null,"publication_date":"2026-09-24","publication_year":2026,"doi":"10.11588/heidok.00039377","pubmed_id":null,"openalex_id":"https://openalex.org/W7214153504","source_url":"https://doi.org/10.11588/heidok.00039377","substance_tags":"psilocybin","topic_tags":"Depression,Pharmacology,Mechanism of Action,Treatment-Resistant Depression,Safety","study_type":"Other","source_name":"OpenAlex","publication_status":"published","date_added":"2026-09-26 01:20:21","last_checked":"2026-10-01 01:20:28","bibtex":null,"source_record_id":"DOI:10.11588/heidok.00039377","abstract_available":false,"abstract_source":null,"abstract_source_url":null,"abstract_redistributed":false,"text_rights_status":"not_applicable_no_text","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.11588/heidok.00039377","source_url":"https://doi.org/10.11588/heidok.00039377","doi":"10.11588/heidok.00039377","pmid":"","publication_date":"2026-09-24","importer_version":"2.1.3","text_redistributed":false}},{"id":5958,"title":"Age moderates the relationship between psychedelic use and mental health in naturalistic settings","authors":"Giammarco Di Gregorio, Basset Sophia, Harjot Manmohan, Warren C. Nixon, Amrutha Pogaku, Jing Zhou, David J. Sanderson, Michael L. Lengieza, Marco Bocchio","journal":"Scientific Reports","publication_date":"2026-09-24","publication_year":2026,"doi":"10.1038/s41598-026-68283-2","pubmed_id":null,"openalex_id":"https://openalex.org/W7204099123","source_url":"https://doi.org/10.1038/s41598-026-68283-2","substance_tags":"psilocybin","topic_tags":"Depression,Anxiety,Chronic Pain,Aging,Longevity,Mystical Experience,Clinical Trial,Observational Study,Older Adults,Safety,Toxicity","study_type":"Clinical Trial","source_name":"OpenAlex","publication_status":"published","date_added":"2026-09-26 01:20:21","last_checked":"2026-10-01 01:20:28","bibtex":null,"source_record_id":"DOI:10.1038/s41598-026-68283-2","abstract_available":true,"abstract_source":"OpenAlex","abstract_source_url":"https://doi.org/10.1038/s41598-026-68283-2","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.1038/s41598-026-68283-2","source_url":"https://doi.org/10.1038/s41598-026-68283-2","doi":"10.1038/s41598-026-68283-2","pmid":"","publication_date":"2026-09-24","importer_version":"2.1.3","text_redistributed":false}},{"id":5956,"title":"Preclinical Anxiolytic- and Antidepressant-like Effects of α,α-Trehalose, a Bioactive Compound Identified in Psilocybe cubensis","authors":"Aylín R. Tabal-Robles, María Eva González-Trujano, Gabriel Fernando Moreno-Pérez, Alberto Hernández-León, Susana Rojas-Lima, David Martı́nez-Vargas, Hiram Luna-Munguía, Raúl Iván Escamilla-Orozco, Laura Guzmán-Dávalos, José Guadalupe Alvarado-Rodríguez, Jesús Martín Torres-Valencia","journal":"Molecules","publication_date":"2026-09-23","publication_year":2026,"doi":"10.3390/molecules31193383","pubmed_id":null,"openalex_id":"https://openalex.org/W7214086238","source_url":"https://doi.org/10.3390/molecules31193383","substance_tags":"psilocybin,psilocin","topic_tags":"Depression,Anxiety,Pharmacology,Receptor Pharmacology,Animal Study,In Vitro Study,Toxicity","study_type":"Animal Study","source_name":"OpenAlex","publication_status":"published","date_added":"2026-09-25 01:20:21","last_checked":"2026-09-30 01:20:24","bibtex":null,"source_record_id":"DOI:10.3390/molecules31193383","abstract_available":true,"abstract_source":"OpenAlex","abstract_source_url":"https://doi.org/10.3390/molecules31193383","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.3390/molecules31193383","source_url":"https://doi.org/10.3390/molecules31193383","doi":"10.3390/molecules31193383","pmid":"","publication_date":"2026-09-23","importer_version":"2.1.3","text_redistributed":false}},{"id":5953,"title":"ADEPT: Augmenting DBT Effectiveness With Psilocybin-Assisted Therapy","authors":"University of Minnesota","journal":"ClinicalTrials.gov","publication_date":"2026-09-22","publication_year":2026,"doi":null,"pubmed_id":null,"openalex_id":null,"source_url":"https://clinicaltrials.gov/study/NCT07833761","substance_tags":"psilocybin","topic_tags":"Depression,Personality Change,Emotional Processing,Mystical Experience,Safety,Adverse Events","study_type":"Other","source_name":"ClinicalTrials.gov","publication_status":"clinical trial","date_added":"2026-09-23 01:38:32","last_checked":"2026-09-29 01:24:26","bibtex":null,"source_record_id":"https://clinicaltrials.gov/study/NCT07833761","abstract_available":true,"abstract_source":"ClinicalTrials.gov","abstract_source_url":"https://clinicaltrials.gov/study/NCT07833761","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"ClinicalTrials.gov","source_record_id":"https://clinicaltrials.gov/study/NCT07833761","source_url":"https://clinicaltrials.gov/study/NCT07833761","doi":"","pmid":"","publication_date":"2026-09-22","importer_version":"2.1.3","text_redistributed":false}},{"id":5952,"title":"Curious about Psilocybin? Prevalence and correlates of interest among adults with chronic pain.","authors":"Crawford CML, Walsh Z, Louw WF, Holtzman S.","journal":"Authorea Preprints","publication_date":"2026-09-21","publication_year":2026,"doi":"10.22541/authorea.15009173/v1","pubmed_id":null,"openalex_id":null,"source_url":"https://doi.org/10.22541/authorea.15009173/v1","substance_tags":"psilocybin","topic_tags":"Depression,Anxiety,Chronic Pain,Aging,Wellbeing,Observational Study","study_type":"Observational Study","source_name":"Europe PMC","publication_status":"preprint","date_added":"2026-09-23 01:20:25","last_checked":"2026-09-28 01:20:25","bibtex":null,"source_record_id":"DOI:10.22541/authorea.15009173/v1","abstract_available":true,"abstract_source":"Europe PMC","abstract_source_url":"https://doi.org/10.22541/authorea.15009173/v1","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Europe PMC","source_record_id":"DOI:10.22541/authorea.15009173/v1","source_url":"https://doi.org/10.22541/authorea.15009173/v1","doi":"10.22541/authorea.15009173/v1","pmid":"","publication_date":"2026-09-21","importer_version":"2.1.3","text_redistributed":false}},{"id":5950,"title":"Exploring the Therapeutic Potential of Psilocybin: A Comprehensive Review of Clinical Trial Evidence and Implications for Rescheduling.","authors":"Abolhasani F, Rezaiezadeh H, Langarizadeh MA, Tavakoli MR, Ilaghi M, Zare P, Ravari FK, Alamdar F, Banazadeh M, Shabani M.","journal":"Mini reviews in medicinal chemistry","publication_date":"2026-09-18","publication_year":2026,"doi":"10.2174/0113895575443239260828094859","pubmed_id":"42770437","openalex_id":"https://openalex.org/W7213987315","source_url":"https://doi.org/10.2174/0113895575443239260828094859","substance_tags":"psilocybin","topic_tags":"Depression,Anxiety,PTSD,Addiction,Headache / Migraine,Neuroplasticity,Mechanism of Action,Receptor Pharmacology,Wellbeing,Emotional Processing,Clinical Trial,Review Article,Treatment-Resistant Depression,Safety,Adverse Events","study_type":"Clinical Trial","source_name":"Europe PMC","publication_status":"published","date_added":"2026-09-23 01:20:07","last_checked":"2026-09-25 01:20:21","bibtex":null,"source_record_id":"PMID:42770437","abstract_available":true,"abstract_source":"Europe PMC","abstract_source_url":"https://doi.org/10.2174/0113895575443239260828094859","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Europe PMC","source_record_id":"PMID:42770437","source_url":"https://doi.org/10.2174/0113895575443239260828094859","doi":"10.2174/0113895575443239260828094859","pmid":"42770437","publication_date":"2026-09-18","importer_version":"2.1.3","text_redistributed":false}},{"id":5948,"title":"EFFICACY AND SAFETY OF PSILOCYBIN IN TREATMENT-RESISTANT DEPRESSION: A REVIEW","authors":"Gawin Mateusz, Koziara Emilia, Gadzina Mateusz, Gawlak Julia, Krzesimir Kuświk Maciej, Tarnawska Zofia, Figiel Karolina, Sontag Wojciech, Zawisza Mateusz, Golec Aleksandra","journal":"International Journal of Innovative Technologies in Social Science","publication_date":"2026-09-21","publication_year":2026,"doi":"10.31435/ijitss.3(51).2026.6573","pubmed_id":null,"openalex_id":"https://openalex.org/W7213945218","source_url":"https://doi.org/10.31435/ijitss.3(51).2026.6573","substance_tags":"psilocybin,psilocin","topic_tags":"Depression,Neuroplasticity,Mechanism of Action,Receptor Pharmacology,Clinical Trial,Review Article,Treatment-Resistant Depression,Safety,Adverse Events","study_type":"Clinical Trial","source_name":"Crossref","publication_status":"published","date_added":"2026-09-22 01:20:19","last_checked":"2026-09-28 01:20:29","bibtex":null,"source_record_id":"DOI:10.31435/ijitss.3(51).2026.6573","abstract_available":true,"abstract_source":"Crossref","abstract_source_url":"https://doi.org/10.31435/ijitss.3(51).2026.6573","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Crossref","source_record_id":"DOI:10.31435/ijitss.3(51).2026.6573","source_url":"https://doi.org/10.31435/ijitss.3(51).2026.6573","doi":"10.31435/ijitss.3(51).2026.6573","pmid":"","publication_date":"2026-09-21","importer_version":"2.1.3","text_redistributed":false}},{"id":5945,"title":"Targeting the serotonin 1B receptor for the treatment of depression and anxiety.","authors":"Fleury S, Nautiyal KM.","journal":"Expert opinion on therapeutic targets","publication_date":"2026-09-28","publication_year":2026,"doi":"10.1080/14728222.2026.2738183","pubmed_id":"42766349","openalex_id":"https://openalex.org/W7213928055","source_url":"https://doi.org/10.1080/14728222.2026.2738183","substance_tags":"psilocybin","topic_tags":"Depression,Anxiety,End-of-Life Distress,Neuroplasticity,Mechanism of Action,Receptor Pharmacology,Biomarkers,Clinical Trial,Animal Study,Safety,Adverse Events","study_type":"Clinical Trial","source_name":"Europe PMC","publication_status":"published","date_added":"2026-09-22 01:20:05","last_checked":"2026-10-05 01:20:16","bibtex":null,"source_record_id":"PMID:42766349","abstract_available":true,"abstract_source":"Europe PMC","abstract_source_url":"https://doi.org/10.1080/14728222.2026.2738183","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Europe PMC","source_record_id":"PMID:42766349","source_url":"https://doi.org/10.1080/14728222.2026.2738183","doi":"10.1080/14728222.2026.2738183","pmid":"42766349","publication_date":"2026-09-28","importer_version":"2.1.3","text_redistributed":false}},{"id":5942,"title":"An Open-Label, Dose-Escalation Trial of Psilocybin-Assisted Therapy for Bipolar II Depression.","authors":"Downey AE, Szigeti B, Bradley ER, Fernandes-Osterhold G, Sakai K, Llerena K, Fredenburg L, Nerayo J, Evans-Riera L, Nielsen B, Krystal AD, O'Donovan A, Gard DE, Woolley JD.","journal":"The Journal of clinical psychiatry","publication_date":"2026-09-21","publication_year":2026,"doi":"10.4088/jcp.25m16227","pubmed_id":"42765891","openalex_id":"https://openalex.org/W7213540649","source_url":"https://doi.org/10.4088/jcp.25m16227","substance_tags":"psilocybin","topic_tags":"Depression,Anxiety,Headache / Migraine,Safety,Adverse Events","study_type":"Other","source_name":"Europe PMC","publication_status":"published","date_added":"2026-09-19 01:20:18","last_checked":"2026-09-28 01:20:25","bibtex":null,"source_record_id":"PMID:42765891","abstract_available":true,"abstract_source":"Europe PMC","abstract_source_url":"https://doi.org/10.4088/jcp.25m16227","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Europe PMC","source_record_id":"PMID:42765891","source_url":"https://doi.org/10.4088/jcp.25m16227","doi":"10.4088/jcp.25m16227","pmid":"42765891","publication_date":"2026-09-21","importer_version":"2.1.3","text_redistributed":false}},{"id":5936,"title":"Exploratory safety, tolerability, and feasibility of psilocybin-assisted psychotherapy for adults with co-occurring treatment-resistant depression and cluster B personality disorders","authors":"Lipsitz Orly, Brudner Ryan M., Doyle Zoe, Kaczmarek Erica S., Meshkat Shakila, Sethi Rickinder, McIntyre Roger S., Rosenblat Joshua D.","journal":"npj Mental Health Research","publication_date":"2026-09-16","publication_year":2026,"doi":"10.1038/s44184-026-00248-9","pubmed_id":null,"openalex_id":"https://openalex.org/W7213392699","source_url":"https://doi.org/10.1038/s44184-026-00248-9","substance_tags":"psilocybin","topic_tags":"Depression,Personality Change,Treatment-Resistant Depression,Safety","study_type":"Other","source_name":"Crossref","publication_status":"published","date_added":"2026-09-17 01:20:17","last_checked":"2026-09-23 01:20:29","bibtex":null,"source_record_id":"DOI:10.1038/s44184-026-00248-9","abstract_available":true,"abstract_source":"Crossref","abstract_source_url":"https://doi.org/10.1038/s44184-026-00248-9","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Crossref","source_record_id":"DOI:10.1038/s44184-026-00248-9","source_url":"https://doi.org/10.1038/s44184-026-00248-9","doi":"10.1038/s44184-026-00248-9","pmid":"","publication_date":"2026-09-16","importer_version":"2.1.3","text_redistributed":false}}],"total":1783,"page":1,"per_page":20,"pages":90,"resource":"papers","filters":{"q":null,"author":null,"substances":["psilocybin","psilocin"],"topic":"Depression","study_type":null,"cited_doi":null,"sources":[],"publication_statuses":[],"year":null,"journal":null,"from":null,"to":null,"added_from":null,"added_to":null,"sort":"newly_added","page":1,"per_page":"20"}}